Tratamento Quimioterápico Adjuvante no Câncer Operável da Mama

Autores

  • Luiz Eduardo Atalecio Araújo Seção de Oncologia clínica. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil
  • João Luiz Campos Soares Seção de Mastologia. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil
  • Jose Sigiliano Gomes Filho Seção de Mastologia. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil
  • Luiz Antonio Lopes Silveira Seção de Mastologia. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil
  • Marcos Wajnberg Seção de Mastologia. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil
  • Vanna Carneiro Oliveira Seção de Mastologia. Hospital de Oncologia do INAMPS. Rio de Janeiro (RJ), Brasil

DOI:

https://doi.org/10.32635/2176-9745.RBC.1987v33n2.3202

Palavras-chave:

Câncer da Mama, Quimioterapia Adjuvante

Resumo

Em 1981 foi padronizada no Hospital de Oncologia - INAMPS/RIO (H.O.), a conduta terapêutica para o câncer operável da mama. Apresentamos os resultados preliminares obtidos com o tratamento proposto, que consistiu da cirurgia isolada ou associada à quimioterapia adjuvante (Qt adj), em 333 pacientes. A conduta cirúrgica consistiu de mastectomia clássica à Halsted (H) ou modificada tipo Patey (P) e quadrantectomia com esvaziamento axilar (SE). A radioterapia adjuvante ou pós-mastectomia não foi utilizada no presente estudo. A Qt adj consistiu de administração cíclica de ciclo fosfamida, methotrexate e fluorouracil\CMF) endovenosos, repetidos a cada 21/21 dias, por oito ciclos (CMF). Avaliamos e comparamos o intervalo livre de doença (ILD) e a sobrevida (SV) de 139 pacientes que tinham axila histologicamente comprometida (N+), com 53 pacientes do grupo controle (N+ Cl e 141 pacientes cuja axila não apresentava comprometimento metastático ao exame histológico (N—). Examinamos também a incidência de recidivas e metástases bem como a toxicidade decorrente do tratamento com um período médio de follow-up em torno de 20 meses.

Downloads

Não há dados estatísticos.

Referências

Carbone PP Adjuvant therapy of breast cancer 1971 1981 Breast Cancer Res and Treat 1982, 2 7584. DOI: https://doi.org/10.1007/BF01805719

Helimari S et al - Cancer of Breast in De Vila Vi, Heliman S, Posenherg AS Cancer principles and Practice of Oncology (Ed), Philadelphia, J B Lippincott Company, 1982, 27. 914-970

Bluming A - Trealmeni of primary breast cancer without mastectomy Anr J. Med 1982; 72- 820-82. DOI: https://doi.org/10.1016/0002-9343(82)90549-6

Bonadona G - Carcinoma dela mammella in Manuale di Oncologia Medica (Ed) Milano, Masson Italia Edilori 1982; 32 393-415.

Fisher B et al and participating NSABP investigators: Breast cancer studies of NSABP: an editorialized overview. In. Salmon SE, Jones SE Adjuvant Therapy of Cancer 3 (Ed) New York, Grurre and Stratton Inc 1981, 359.369.

Osborns M P et al - Breast conservation in the treatment of early breast cancer. Cancer 1984, 53: 349-355. DOI: https://doi.org/10.1002/1097-0142(19840115)53:2<349::AID-CNCR2820530230>3.0.CO;2-B

Wolmark N, Fisher B - Surgery in lhe primary treatment of breast cancer. Breast Cancer Res and Treat 1981; 339-348 DOI: https://doi.org/10.1007/BF01806749

Bonadorra G, Valagussa P - Adjuvant therapy of primary breast cancer, in Carter SK, Glastein E, Livingston RB. Principles of Cancer treatment (eds) New York, Mc Graw-Hiil. Inc 1982; 315-326

Bedwinsk J - Adjuvant irradiation for eariy breast cancer. Cancer, 1984; 53. 729-739 DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<729::AID-CNCR2820531322>3.0.CO;2-R

Harris JR, Beadie GF, Heliman 5 Clinical studies on lhe use of radiation therapy as primary treatment of early breast cancer, Cancer, 1984, 53: 705-711. DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<705::AID-CNCR2820531319>3.0.CO;2-L

Levine JM et ai - Tbe effect of postoperative and primary radiation therapy on delivered dose of adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) chemotherapy in breast cancer. Cancer, 1984, 53. 237-241. DOI: https://doi.org/10.1002/1097-0142(19840115)53:2<237::AID-CNCR2820530209>3.0.CO;2-Y

Muss H et al. - Long-term follow-up of L-PAM and CMF witb and without radiation therapy (RT) as adjuvant treatment for stage II breast carcinoma ASCO Abstracts C457, 1984.

Fisher B, other NSABP investigators: Relation of number of positive axillary nodes to the prognosis of patients with breast cancer. Cancer 1983; 52 1.551-1 557. DOI: https://doi.org/10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3

Fisher E et al, collaborating NSABP investigators Parhoiogic findings from the NSABP for breast cancers protoc n. 4 Cancer 1984, 53: 712-723 DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<712::AID-CNCR2820531320>3.0.CO;2-I

Morrow M et al - Does clearing of axillary lymph nodes contribute to accurate stating of breast carcinoma? Cancer 1984, 53 1 329-1.332. DOI: https://doi.org/10.1002/1097-0142(19840315)53:6<1329::AID-CNCR2820530618>3.0.CO;2-U

Salvatori B et al - Prognostic factors in operable breast cancer. Tumori 1983; 69. 477-484 DOI: https://doi.org/10.1177/030089168306900518

Nissen-Meyer R et al - Surgical adjuvant chemotherapy resuits of one short course with cyciophosphamide after mastectomy for breast cancer. Ano Surg. 1961; 154: 629-647. DOI: https://doi.org/10.1097/00000658-196110000-00012

Montagne ED - Conservation surgery and radiation therapy in lhe treatment of operable breast cancer. Cancer 1984, 53: 700-704. DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<700::AID-CNCR2820531318>3.0.CO;2-2

Senn HJ - Current status and indications for adjuvant therapy in breast cancer, Cancer Chemother. Pharmacol. 1982; 8: 139-150. DOI: https://doi.org/10.1007/BF00255474

Cedermark B et al - Breast conserving treatment for breast cancer in Stockhoim, Sweden, 1977 to 1981. Cancer 1984? 53: 1.253-1.255 DOI: https://doi.org/10.1002/1097-0142(19840315)53:6<1253::AID-CNCR2820530606>3.0.CO;2-I

Hartmann WH - Minimal breast cancer. Cancer 1984; 53: 681-684. DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<681::AID-CNCR2820531315>3.0.CO;2-3

Kinne DW - Surgical management of clinicaly early breast cancer Cancer 1984; 53. 685-690. DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<685::AID-CNCR2820531316>3.0.CO;2-P

Lagios MD et al - Segmental mastectomy without radiotherapy. Cancer 1983; 52: 2.173-2.179. DOI: https://doi.org/10.1002/1097-0142(19831201)52:11<2173::AID-CNCR2820521133>3.0.CO;2-0

Lichter A et al - A randomized comparison of mastectomy iMI pius axiiary dissection (AD) versus excision (E), AD, pius radiation (XRT) in lhe treatment of primary breast cancer. ASCO Absrracts C 469, 1984.

Sarrazin D et al - Conservative teatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less Cancer 1984; 53: 1209-12 13 DOI: https://doi.org/10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y

International Union Against Cancer Committee on TNM classification of Malignant Tumours. Second edition. Geneva, international Union Against Cancer, 1974.

Hakes T and cols - Confirmation of dose-survival relationship in breast adjuvante chemotherapy. ASCO Abstracts C 477, 1984.

Kaplan EL, Meyer P - Non pararnetric estimation from incomplete observation Am. Statist. Assoc. J 1958,53 457-481. DOI: https://doi.org/10.1080/01621459.1958.10501452

Manter M - Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother. Rep. 1966; 50: 163-170.

Downloads

Publicado

2023-08-04

Como Citar

1.
Araújo LEA, Soares JLC, Gomes Filho JS, Silveira LAL, Wajnberg M, Oliveira VC. Tratamento Quimioterápico Adjuvante no Câncer Operável da Mama. Rev. Bras. Cancerol. [Internet]. 4º de agosto de 2023 [citado 2º de novembro de 2024];33(2):167-76. Disponível em: https://rbc.inca.gov.br/index.php/revista/article/view/3202

Edição

Seção

ARTIGO ORIGINAL